Numinus Wellness Inc. Reports Q2 2023 Results Post published:April 14, 2023 Post category:Press Release
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) Post published:April 13, 2023 Post category:Press Release
FILAMENT HEALTH AND PHARMALA BIOTECH ANNOUNCE RELEASE OF GMP MDMA CAPSULES Post published:April 11, 2023 Post category:Press Release
Numinus Launches new Clinic Licensing Platform, the Numinus Network, to Accelerate Expansion Post published:April 11, 2023 Post category:Press Release
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Post published:April 10, 2023 Post category:Press Release
COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference Post published:April 10, 2023 Post category:Press Release
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research Post published:April 10, 2023 Post category:Press Release
Psychedelic Bulletin #135: A Misguided MDMA Price-Fixing Effort; Psilocybin Study’s Lukewarm Results; Dutch Government Forms MDMA Commission; Trouble at Empyrean? Post published:April 9, 2023 Post category:Psychedelic Bulletin
Clearmind Medicine Closes US$3.5 Million Public Offering Post published:April 6, 2023 Post category:Press Release
Psychedelic Research Bulletin: March 2023 Post published:April 5, 2023 Post category:Psychedelics Research Review